Effect of different hemodialysis modalities on hepcidin clearance in patients undergoing maintenance hemodialysis

Abstract Introduction Hepcidin is a master regulator of iron utilization and takes part in the pathophysiology of anemia in maintenance hemodialysis (MHD) patients. Hepcidin is a moderate‐molecular‐weight substance and partially binds to plasma proteins in the circulation, which theoretically might be removed efficiently by hemoperfusion (HP). This study aimed to compare the effect of different dialysis modalities on hepcidin removal and discuss its effect on the iron and anemia status in MHD patients. Materials and Methods In a longitudinal interventional study of 26 stable MHD patients, the serum hepcidin, β2‐microglobulin (β2‐MG), and intact parathyroid hormone (iPTH) were measured before and after one treatment session of hemodialysis (HD), hemodiafiltration (HDF), HD + HP, and HDF + HP, separately. One‐way analysis of variance (ANOVA) was used to identify the effect of dialysis modalities on the intra‐dialysis clearance ratios. Results The combined dialysis modalities (HD + HP and HDF + HP) achieved greater clearance ratios of serum hepcidin than HD and HDF alone, HD + HP vs. HD (16 ± 15% vs. 4 ± 13%, p < 0.001), HDF + HP vs. HDF (18 ± 5% vs. 10 ± 13%, p = 0.0036). Similarly, the combined dialysis modalities also performed better than HD and HDF alone in removing β2‐MG. There was no significant difference in iPTH clearance among these four modalities, except that HDF + HP achieved a greater clearance ratio than HD. Furthermore, the anemia was improved after the 6‐month treatment with regular HD/HDF plus HP, which was indicated by increasing hemoglobin ( p = 0.0004) and reduction of erythropoiesis‐stimulating agents (ESAs) resistance index (ERI) ( p = 0.0431). Conclusions Our findings suggest that the combined dialysis modalities of HD/HDF plus HP could achieve better clearance ratios of hepcidin than HD/HDF alone, thereby, might improve iron utilization, and benefit anemia management in MHD patients. Further studies with larger sample‐size patients and longer follow‐up duration are still needed.